OmniAb and PepGen Q4 Results Highlight Divergent Biotech Growth Strategies
Key Takeaways
- OmniAb and PepGen reported full-year 2025 results, showcasing the health of the antibody discovery and neuromuscular therapeutics sectors.
- While OmniAb focuses on platform scalability and royalty streams, PepGen emphasizes clinical execution and cash preservation for its lead candidates.
Key Intelligence
Key Facts
- 1OmniAb reported a significant increase in active partner programs, surpassing 310 by year-end 2025.
- 2PepGen maintained a robust cash position, with a projected runway extending into late 2027.
- 3OmniAb's revenue growth was driven by a 15% year-over-year increase in milestone and royalty-bearing events.
- 4PepGen successfully completed enrollment for its Phase 2 CONNECT1 trial in Duchenne Muscular Dystrophy.
- 5Both companies reported a decrease in general and administrative expenses as a percentage of total revenue/spend.
| Metric/Feature | ||
|---|---|---|
| Business Model | Platform-as-a-Service | Clinical Drug Developer |
| Core Technology | Transgenic Animals (OmniRat) | EDO Delivery Platform |
| Primary Revenue | Royalties & Milestones | Future Product Sales/Partnering |
| Key Focus 2026 | Pipeline Maturation | Clinical Data Readouts |
Analysis
The fourth-quarter and full-year 2025 financial results from OmniAb and PepGen provide a comprehensive look at the two primary engines of the modern biotechnology sector: the scalable platform provider and the clinical-stage drug developer. As the industry moves further into 2026, these reports underscore a market that increasingly rewards operational efficiency and clear paths to commercialization over speculative growth. OmniAb’s performance highlights the resilience of the 'picks and shovels' model, while PepGen’s results reflect the high-stakes nature of precision medicine in the neuromuscular space.
OmniAb’s 2025 results were characterized by the continued expansion of its partner-funded portfolio. The company’s unique value proposition—providing access to a suite of transgenic animals like OmniRat and OmniChicken for antibody discovery—has allowed it to build a massive pipeline of over 300 active programs without the direct R&D costs associated with clinical trials. In 2025, the focus shifted toward the maturation of this pipeline, with several partner programs moving into late-stage clinical trials and early commercialization phases. This transition is critical for OmniAb, as it signals the beginning of a more significant royalty-driven revenue phase, which offers higher margins than traditional licensing and milestone payments.
The fourth-quarter and full-year 2025 financial results from OmniAb and PepGen provide a comprehensive look at the two primary engines of the modern biotechnology sector: the scalable platform provider and the clinical-stage drug developer.
In contrast, PepGen’s year-end report centered on the clinical execution of its Enhanced Delivery Oligonucleotide (EDO) platform. For a clinical-stage firm like PepGen, the primary metrics of success are clinical data integrity and cash runway. Throughout 2025, PepGen made significant strides in its PGN-EDO51 program for Duchenne Muscular Dystrophy (DMD) and its PGN-EDO1 program for Myotonic Dystrophy Type 1 (DM1). The company’s ability to manage its burn rate while advancing these complex therapies is a testament to its disciplined capital allocation. Investors are particularly focused on the safety and efficacy data from the CONNECT1 and FREEDOM-DM1 trials, which will determine the company's valuation trajectory in the coming year.
What to Watch
The broader market context for these earnings is a biotech sector that has stabilized following the volatility of the early 2020s. Higher interest rates in previous years forced companies to prioritize 'must-have' technologies. OmniAb benefited from this trend as pharmaceutical giants looked to outsource discovery to proven platforms to save time and capital. Meanwhile, PepGen’s focus on rare diseases with high unmet needs has insulated it somewhat from the broader pricing pressures seen in more crowded therapeutic areas.
Looking ahead to the remainder of 2026, the divergence between these two models will likely sharpen. OmniAb is positioned to benefit from a 'network effect,' where each new partnership validates the platform and attracts further collaborators. The key risk remains the clinical success of its partners; if a major partner program fails, it could dampen royalty expectations. For PepGen, the focus remains squarely on data. The next 12 months are a 'proof-of-concept' period for the EDO platform. Success in DMD and DM1 would not only validate their lead candidates but also suggest that the EDO technology could be applied to a wider range of genetic diseases, potentially making PepGen an attractive acquisition target for larger biopharma players seeking to bolster their RNA therapeutics portfolios.
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |